Stock Details
SNY is Sanofi's stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 42.55$. Average daily volumn in 3 months 3.05M. Market cap 99.99B

Stock symbol : SNY. Exchange : NasdaqGS. Currency : USD
Lastest price : 40.12$. Total volume : 3.04M. Market state PREPRE
Click reload if you want to check the lastest price on market!!!

Sanofi (SNY)
Last Price

Previous Close39.19
Day Range39.51-40.19
Bid0.00 x 2.2k
Ask0.00 x 1.1k
Average Volume3.05M
Market Cap99.99B
52 Week Range36.91-58.10
Trailing P/E15.61
Foward P/E9.10
Dividend (Yield %)4.59%
Ex-Dividend Date2022-05-26

Financial Details

According to Sanofi's financial reports the company's revenue in 2021 were 39.17B an increase( +5.41%) over the years 2020 revenue that were of 37.37B. In 2021 the company's total earnings were 6.22B while total earnings in 2020 were 12.29B(-50%).

Loading ...


Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines ... for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Market Cap:
Total Assets:
Total Cash:

News about "Sanofi"


Sanofi exec jumps to Owkin to ramp up the AI biotech’s pharma partnership plans

Source from : MedCity News - 13 hours ago

As Sanofi’s top business partnering executive, Alban de La Sablière led the pharmaceutical giant’s collaboration talks with numerous companies, including $30 billion in acquisitions in the pa ...See details»


Sanofi li­cens­es a pre­clin­i­cal ge­net­ic dis­ease drug from an un­known biotech spun out of the NIH

Source from : ENDPOINTS NEWS - 1 days ago

In a new deal Tuesday morning, Sanofi is jumping into the antibody-RNA conjugate (ARC) space and elevating a little-known private biotech into the spotlight. Sanofi is licensing a preclinical ARC ...See details»


Sanofi (SNY) Relies on Dupixent and Vaccines to Drive Growth

Source from : YAHOO!Finance - 23 hours ago

Sanofi possesses a leading vaccine portfolio, which has become the primary top-line driver. Its R&D pipeline is strong.See details»


Sanofi’s RNA therapies strategy adds new piece with alliance in muscular dystrophy

Source from : MedCity News - 20 hours ago

Sanofi is collaborating with startup miRecule to develop an RNA therapy for facioscapulohumeral muscular dystrophy. The pharmaceutical giant gets global rights to miRecule’s therapy for this type of ...See details»


Sanofi In-Licenses Preclinical Genetic Disease Candidate From An Unknown Biotech

Source from : YAHOO!Finance - 18 hours ago

French pharma major Sanofi SA (NASDAQ: SNY) entered into a collaboration and licensing agreement with little-known U.S. biotech miRecule, an innovator of next-generation RNA therapeutics. Under the ...See details»


Cambridge Investment Research Advisors Inc. Has $1.18 Million Stock Holdings in Sanofi (NASDAQ:SNY)

Source from : Defense World - 1 days ago

Cambridge Investment Research Advisors Inc. lowered its holdings in shares of Sanofi (NASDAQ:SNY – Get Rating) by 4.2% in the second quarter, according to its most recent 13F filing with the SEC. The ...See details»


UMB Bank n.a. Lowers Holdings in Sanofi (NASDAQ:SNY)

Source from : Defense World - 1 days ago

UMB Bank n.a. reduced its position in Sanofi (NASDAQ:SNY – Get Rating) by 4.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The ...See details»


Sanofi, Re­gen­eron’s Dupix­ent scores an­oth­er in­di­ca­tion with first-ever ap­proval for nodu­lar skin dis­or­der

Source from : ENDPOINTS NEWS - 5 days ago

Sanofi chief executive Paul Hudson told investors earlier this year that the Big Pharma was going to emphasize its sales kingpin Dupixent moving forward. He wasn't joking — the megablockbuster drug ...See details»


Sanofi's (SNY) Dupixent Gets FDA Nod for Prurigo Nodularis

Source from : Yahoo! Sports - 5 days ago

The FDA approves Sanofi (SNY) and its partner Regeneron's Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis.See details»


Sanofi partners with Scribe to gain gene editing tools for cell therapy work

Source from : BioPharma Dive - 7 days ago

The California biotech will receive $25 million upfront from Sanofi, which plans to use Scribe’s platform to edit natural killer cells for cancer treatment.See details»

Sanofi (SNY) Stock Moves -0.45%: What You Should Know

Source from : Nasdaq - 5 days ago

Sanofi (SNY) closed at $38 in the latest trading session, marking a -0.45% move from the prior day. This move was narrower than the S&P 500's daily loss of 2.11%. Elsewhere, the Dow lost 1.54% ...See details»


French Drugmaker Sanofi Expects Positive Boost From Currency Markets in Q3

Source from : U.S. News & World Report - 7 days ago

PARIS (Reuters) -French drugmaker Sanofi said it expected a positive boost to its third-quarter business results from movements on the currency markets, helped by the strength of the U.S. dollar since ...See details»

Sanofi, Scribe Launch Up-to-$1B CRISPR-Based Cancer NK Cell Therapy Collaboration

Source from : GEN - 7 days ago

Scribe Therapeutics Co-Founder, President and CEO Benjamin L. Oakes, PhD Sanofi and Scribe Therapeutics will partner to develop CRISPR-based cell therapies to fight cancer, the companies said today.See details»

PSHAN, SANOFI Sign Agreement to Undertake COVID-19 Vaccine Hesitancy Assessment in Nigeria

Source from : This Day - 2 days ago

The Private Sector Health Alliance of Nigeria (PSHAN) and SANOFI have signed an agreement to undertake a 6 months COVID-19 Vaccine Hesitancy Assessment in Nigeria (C19-VHAN). The study which would ...See details»